Boehringer Ingelheim Corporation Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals, Inc. Clinical Collaboration ) investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus ... (more)
http://www.biospace.com/news_story.aspx?StoryID=308193&full=1
http://www.biospace.com/news_story.aspx?StoryID=308193&full=1
No comments:
Post a Comment